Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure

Arata Fukushima, Shintaro Kinugawa, Tsuneaki Homma, Yoshihiro Masaki, Takaaki Furihata, Takashi Yokota, Shouji Matsushima, Shingo Takada, Tomoyasu Kadoguchi, Koji Oba, Koichi Okita, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Brain-derived neurotropic factor (BDNF) is involved in cardiovascular diseases as well as skeletal muscle energy metabolism and depression. We investigated whether serum BDNF level was associated with prognosis in patients with heart failure (HF). Methods and Results We measured the serum BDNF level in 58 patients with HF (59.2 ± 13.7 years old, New York Heart Association functional class I-III) at baseline, and adverse events, including all cardiac deaths and HF rehospitalizations, were recorded during the median follow-up of 20.3 months. In a univariate analysis, serum BDNF levels were significantly associated with peak oxygen capacity (β = 0.547; P =.003), anaerobic threshold (β = 0.929; P =.004), and log minute ventilation/carbon dioxide production slope (β = -10.15; P =.005), but not Patient Health Questionnaire scores (β = -0.099; P =.586). A multivariate analysis demonstrated that serum BDNF level was an independent prognostic factor of adverse events (hazard ratio 0.41, 95% confidence interval 0.20-0.84; P =.003). The receiver operating characteristic curve demonstrated that low levels of BDNF (<17.4 ng/mL) were associated with higher rates of adverse events compared with high levels of BDNF (≥17.4 ng/mL; log rank test: P <.001). Conclusions Decreased serum BDNF levels were significantly associated with adverse outcomes in HF patients, suggesting that these levels can be a useful prognostic biomarker.

Original languageEnglish
Pages (from-to)300-306
Number of pages7
JournalJournal of Cardiac Failure
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 1 2015
Externally publishedYes

Fingerprint

Heart Failure
Brain
Serum
Anaerobic Threshold
Carbon Dioxide
ROC Curve
Energy Metabolism
Ventilation
Skeletal Muscle
Cardiovascular Diseases
Multivariate Analysis
Biomarkers
Confidence Intervals
Oxygen
Health

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure. / Fukushima, Arata; Kinugawa, Shintaro; Homma, Tsuneaki; Masaki, Yoshihiro; Furihata, Takaaki; Yokota, Takashi; Matsushima, Shouji; Takada, Shingo; Kadoguchi, Tomoyasu; Oba, Koji; Okita, Koichi; Tsutsui, Hiroyuki.

In: Journal of Cardiac Failure, Vol. 21, No. 4, 01.04.2015, p. 300-306.

Research output: Contribution to journalArticle

Fukushima, A, Kinugawa, S, Homma, T, Masaki, Y, Furihata, T, Yokota, T, Matsushima, S, Takada, S, Kadoguchi, T, Oba, K, Okita, K & Tsutsui, H 2015, 'Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure', Journal of Cardiac Failure, vol. 21, no. 4, pp. 300-306. https://doi.org/10.1016/j.cardfail.2015.01.003
Fukushima, Arata ; Kinugawa, Shintaro ; Homma, Tsuneaki ; Masaki, Yoshihiro ; Furihata, Takaaki ; Yokota, Takashi ; Matsushima, Shouji ; Takada, Shingo ; Kadoguchi, Tomoyasu ; Oba, Koji ; Okita, Koichi ; Tsutsui, Hiroyuki. / Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure. In: Journal of Cardiac Failure. 2015 ; Vol. 21, No. 4. pp. 300-306.
@article{3fa3c3ef8cf14bf980e0c0be780cbce8,
title = "Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure",
abstract = "Background Brain-derived neurotropic factor (BDNF) is involved in cardiovascular diseases as well as skeletal muscle energy metabolism and depression. We investigated whether serum BDNF level was associated with prognosis in patients with heart failure (HF). Methods and Results We measured the serum BDNF level in 58 patients with HF (59.2 ± 13.7 years old, New York Heart Association functional class I-III) at baseline, and adverse events, including all cardiac deaths and HF rehospitalizations, were recorded during the median follow-up of 20.3 months. In a univariate analysis, serum BDNF levels were significantly associated with peak oxygen capacity (β = 0.547; P =.003), anaerobic threshold (β = 0.929; P =.004), and log minute ventilation/carbon dioxide production slope (β = -10.15; P =.005), but not Patient Health Questionnaire scores (β = -0.099; P =.586). A multivariate analysis demonstrated that serum BDNF level was an independent prognostic factor of adverse events (hazard ratio 0.41, 95{\%} confidence interval 0.20-0.84; P =.003). The receiver operating characteristic curve demonstrated that low levels of BDNF (<17.4 ng/mL) were associated with higher rates of adverse events compared with high levels of BDNF (≥17.4 ng/mL; log rank test: P <.001). Conclusions Decreased serum BDNF levels were significantly associated with adverse outcomes in HF patients, suggesting that these levels can be a useful prognostic biomarker.",
author = "Arata Fukushima and Shintaro Kinugawa and Tsuneaki Homma and Yoshihiro Masaki and Takaaki Furihata and Takashi Yokota and Shouji Matsushima and Shingo Takada and Tomoyasu Kadoguchi and Koji Oba and Koichi Okita and Hiroyuki Tsutsui",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.cardfail.2015.01.003",
language = "English",
volume = "21",
pages = "300--306",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure

AU - Fukushima, Arata

AU - Kinugawa, Shintaro

AU - Homma, Tsuneaki

AU - Masaki, Yoshihiro

AU - Furihata, Takaaki

AU - Yokota, Takashi

AU - Matsushima, Shouji

AU - Takada, Shingo

AU - Kadoguchi, Tomoyasu

AU - Oba, Koji

AU - Okita, Koichi

AU - Tsutsui, Hiroyuki

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background Brain-derived neurotropic factor (BDNF) is involved in cardiovascular diseases as well as skeletal muscle energy metabolism and depression. We investigated whether serum BDNF level was associated with prognosis in patients with heart failure (HF). Methods and Results We measured the serum BDNF level in 58 patients with HF (59.2 ± 13.7 years old, New York Heart Association functional class I-III) at baseline, and adverse events, including all cardiac deaths and HF rehospitalizations, were recorded during the median follow-up of 20.3 months. In a univariate analysis, serum BDNF levels were significantly associated with peak oxygen capacity (β = 0.547; P =.003), anaerobic threshold (β = 0.929; P =.004), and log minute ventilation/carbon dioxide production slope (β = -10.15; P =.005), but not Patient Health Questionnaire scores (β = -0.099; P =.586). A multivariate analysis demonstrated that serum BDNF level was an independent prognostic factor of adverse events (hazard ratio 0.41, 95% confidence interval 0.20-0.84; P =.003). The receiver operating characteristic curve demonstrated that low levels of BDNF (<17.4 ng/mL) were associated with higher rates of adverse events compared with high levels of BDNF (≥17.4 ng/mL; log rank test: P <.001). Conclusions Decreased serum BDNF levels were significantly associated with adverse outcomes in HF patients, suggesting that these levels can be a useful prognostic biomarker.

AB - Background Brain-derived neurotropic factor (BDNF) is involved in cardiovascular diseases as well as skeletal muscle energy metabolism and depression. We investigated whether serum BDNF level was associated with prognosis in patients with heart failure (HF). Methods and Results We measured the serum BDNF level in 58 patients with HF (59.2 ± 13.7 years old, New York Heart Association functional class I-III) at baseline, and adverse events, including all cardiac deaths and HF rehospitalizations, were recorded during the median follow-up of 20.3 months. In a univariate analysis, serum BDNF levels were significantly associated with peak oxygen capacity (β = 0.547; P =.003), anaerobic threshold (β = 0.929; P =.004), and log minute ventilation/carbon dioxide production slope (β = -10.15; P =.005), but not Patient Health Questionnaire scores (β = -0.099; P =.586). A multivariate analysis demonstrated that serum BDNF level was an independent prognostic factor of adverse events (hazard ratio 0.41, 95% confidence interval 0.20-0.84; P =.003). The receiver operating characteristic curve demonstrated that low levels of BDNF (<17.4 ng/mL) were associated with higher rates of adverse events compared with high levels of BDNF (≥17.4 ng/mL; log rank test: P <.001). Conclusions Decreased serum BDNF levels were significantly associated with adverse outcomes in HF patients, suggesting that these levels can be a useful prognostic biomarker.

UR - http://www.scopus.com/inward/record.url?scp=84926623683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926623683&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2015.01.003

DO - 10.1016/j.cardfail.2015.01.003

M3 - Article

C2 - 25639689

AN - SCOPUS:84926623683

VL - 21

SP - 300

EP - 306

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 4

ER -